Key result
IVIG, immunosuppression, and intensive rehabilitation successfully reverse severe statin-induced necrotizing myositis with heart failure.
Why the study?
Statin-induced necrotising myositis is a rare but severe complication without standardised treatment guidelines, presenting with muscle weakness and heart failure.
Case Report (n=1)
Statin use can rarely cause severe necrotising myositis with heart failure, which may be managed with immunosuppressants and multidisciplinary rehabilitation.
May support IVIG and immunosuppressants in rare statin-induced myositis with HF; hypothesis-generating, needs prospective confirmation.
Statins are widely prescribed for both the primary and secondary prevention of cardiovascular diseases. However, muscle-related side effects, including weakness, pain and myopathy, are common side effects of statins, reported in up to 5% of users. Here, we present the case of a rare but severe complication of statin use, statin-induced necrotising myositis, which manifested as severe muscle weakness, heart failure and significant morbidity. There are no standardised treatment guidelines for statin-induced myositis. Here, the patient was managed with intravenous immunoglobulin and other immunosuppressants, leading to a favourable outcome when combined with a multidisciplinary approach with physiotherapy, occupational therapy and long-term rehabilitation. Although the patient did not recover full muscle power, he manages at home with the support of walking aids and family.
No takes yet. Share an insight, caveat, or question.
Jeffrey et al. (2025) conducted a case report in Statin-induced necrotising myositis with heart failure (n=1). Statins was evaluated. A patient with severe statin-induced necrotising myositis and heart failure was successfully managed with intravenous immunoglobulin, immunosuppressants, and multidisciplinary rehabilitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: